ARTICLE | Company News
Amgen, Kinetix deal
October 23, 2000 7:00 AM UTC
AMGN will acquire Kinetix, which is focused on small molecule inhibitors of protein kinases, for $170 million in stock. AMGN said the acquisition will support its in-house rational drug design platfor...